| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
|
Prochazka, Katharina T.
|
|
|
15 |
1 |
p. 45-48
|
artikel
|
| 2 |
BTKi, venetoclax, obinutuzumab: what is the ideal combination?
|
Heintel, Daniel
|
|
|
15 |
1 |
p. 49-52
|
artikel
|
| 3 |
Cardiotoxicity—current recommendations of prevention and treatment
|
Bergler-Klein, Jutta
|
|
|
15 |
1 |
p. 67-71
|
artikel
|
| 4 |
Checkpoint inhibitor pneumonitis: Short review of literature and case report
|
Wass, Romana Elisabeth
|
|
|
15 |
1 |
p. 62-66
|
artikel
|
| 5 |
Chronic myeloid leukemia associated with acquired von Willebrand syndrome: A case report
|
Mohapatra, Prachi
|
|
|
15 |
1 |
p. 79-82
|
artikel
|
| 6 |
Clinical challenges in the management of endocrine side effects of immuno-oncological therapies
|
Wolf, Peter
|
|
|
15 |
1 |
p. 72-75
|
artikel
|
| 7 |
Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma
|
Xiao, Xiao
|
|
|
15 |
1 |
p. 90-93
|
artikel
|
| 8 |
Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome
|
Urban, Iveta
|
|
|
15 |
1 |
p. 5-11
|
artikel
|
| 9 |
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
|
Scheiner, Bernhard
|
|
|
15 |
1 |
p. 58-61
|
artikel
|
| 10 |
Immunotherapy—another breakthrough in gastrointestinal malignancies
|
Lenzi, Monika
|
|
|
15 |
1 |
p. 20-25
|
artikel
|
| 11 |
Innovative strategies in gastrointestinal cancer
|
Prager, Gerald
|
|
|
15 |
1 |
p. 1-2
|
artikel
|
| 12 |
Innovative strategies in metastatic gastric cancer: a short review
|
Puhr, Hannah Christina
|
|
|
15 |
1 |
p. 29-34
|
artikel
|
| 13 |
Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature
|
Schlick, Konstantin
|
|
|
15 |
1 |
p. 26-28
|
artikel
|
| 14 |
New actionable targets and investigational drugs in chronic lymphocytic leukemia
|
Bohn, Jan-Paul
|
|
|
15 |
1 |
p. 53-57
|
artikel
|
| 15 |
New frontiers in chronic lymphocytic leukemia on the way to curing the disease
|
Staber, Philipp
|
|
|
15 |
1 |
p. 3
|
artikel
|
| 16 |
Palliative care: patient’s autonomy in the end-of-life situation
|
Engelhardt, Bert
|
|
|
15 |
1 |
p. 76-78
|
artikel
|
| 17 |
Practice-changing strategies in the treatment of esophageal cancer
|
Müldür, Ercan
|
|
|
15 |
1 |
p. 35-38
|
artikel
|
| 18 |
The outcome of COVID-19 in patients with hematological malignancy
|
Tığlıoğlu, Pınar
|
|
|
15 |
1 |
p. 83-89
|
artikel
|
| 19 |
Thyroid metastasectomy for deposits from colorectal cancer: case report and non-systematic review
|
Elnahas, Waleed
|
|
|
15 |
1 |
p. 12-19
|
artikel
|
| 20 |
Toxicity management in severe and refractory cases—what we have learned
|
Preusser, Matthias
|
|
|
15 |
1 |
p. 4
|
artikel
|
| 21 |
Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations
|
Schöche, Johannes
|
|
|
15 |
1 |
p. 39-44
|
artikel
|
Tijdschrift beschrijving